Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06760637 | Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease(FourLight-3) | active not recruiting | Phase 3 | 1,035 | PfizerINDUSTRY | 30 | May 19, 2026 | clinicaltrials |
| NCT04622319 | A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) | active not recruiting | Phase 3 | 1,600 | Daiichi SankyoINDUSTRY |
| 31 |
| May 15, 2026 |
| clinicaltrials |
| NCT05374512 | A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) | active not recruiting | Phase 3 | 644 | AstraZenecaINDUSTRY | 23 | May 15, 2026 | clinicaltrials |
| NCT05347134 | SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer | active not recruiting | Phase 3 | 254 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06968585 | A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy(A166) | active not recruiting | Phase 3 | 365 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT04175210 | Prospective Randomized Study of Accelerated Radiation Therapy (PRART)(PRART) | active not recruiting | Phase 3 | 397 | Weill Medical College of Cornell UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT02488967 | Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer | active not recruiting | Phase 3 | 782 | NRG OncologyOTHER | 2 | May 6, 2026 | clinicaltrials |
| NCT02918084 | CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer(GIM10-CONSENT) | active not recruiting | Phase 3 | 1,000 | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, ItalyOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT01202851 | Relaxation for Women With Breast Cancer Undergoing Radiotherapy | active not recruiting | Phase 3 | 681 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT00433420 | Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer | active not recruiting | Phase 3 | 2,000 | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, ItalyOTHER | 0 | Apr 30, 2026 | clinicaltrials |
| NCT01905046 | Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer | active not recruiting | Phase 3 | 86 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05705401 | Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer(HERO) | active not recruiting | Phase 3 | 1,300 | NRG OncologyOTHER | 2 | Apr 27, 2026 | clinicaltrials |
| NCT03155997 | Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer(monarchE) | active not recruiting | Phase 3 | 5,637 | Eli Lilly and CompanyINDUSTRY | 38 | Apr 24, 2026 | clinicaltrials |
| NCT06062810 | Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms(Drugs-SNPs) | active not recruiting | Phase 2 / Phase 3 | 600 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04595565 | Sacituzumab Govitecan in Primary HER2-negative Breast Cancer(SASCIA) | active not recruiting | Phase 3 | 1,332 | GBG Forschungs GmbHOTHER | 7 | Apr 22, 2026 | clinicaltrials |
| NCT03927027 | Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection | active not recruiting | Phase 3 | 534 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05780567 | Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer | active not recruiting | Phase 3 | 1,946 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04650581 | Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor(FINER) | active not recruiting | Phase 3 | 250 | Canadian Cancer Trials GroupNETWORK | 3 | Apr 13, 2026 | clinicaltrials |
| NCT05382299 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer(ASCENT-03) | active not recruiting | Phase 3 | 623 | Gilead SciencesINDUSTRY | 30 | Apr 6, 2026 | clinicaltrials |
| NCT04851613 | Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer | active not recruiting | Phase 3 | 256 | Laekna LimitedINDUSTRY | 2 | Apr 2, 2026 | clinicaltrials |
| NCT02089100 | Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer(STEREO-SEIN) | active not recruiting | Phase 3 | 154 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05654623 | A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer(VERITAC-2) | active not recruiting | Phase 3 | 624 | PfizerINDUSTRY | 31 | Mar 18, 2026 | clinicaltrials |
| NCT01349322 | Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery | active not recruiting | Phase 3 | 2,354 | Radiation Therapy Oncology GroupNETWORK | 8 | Mar 5, 2026 | clinicaltrials |
| NCT03414970 | Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer | active not recruiting | Phase 3 | 898 | Alliance for Clinical Trials in OncologyOTHER | 2 | Feb 24, 2026 | clinicaltrials |
| NCT05316324 | A Study of the Use of Acellular Dermal Matrix for Breast Reconstruction | active not recruiting | Phase 3 | 353 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT01674140 | S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer(e3) | active not recruiting | Phase 3 | 1,939 | SWOG Cancer Research NetworkNETWORK | 2 | Feb 10, 2026 | clinicaltrials |
| NCT05501886 | Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)(VIKTORIA-1) | active not recruiting | Phase 3 | 701 | Celcuity IncINDUSTRY | 23 | Feb 10, 2026 | clinicaltrials |
| NCT05909397 | Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer(VERITAC-3) | active not recruiting | Phase 3 | 59 | PfizerINDUSTRY | 10 | Feb 10, 2026 | clinicaltrials |
| NCT04639986 | Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | active not recruiting | Phase 3 | 331 | Gilead SciencesINDUSTRY | 3 | Feb 9, 2026 | clinicaltrials |
| NCT02763566 | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer(MONARCH plus) | active not recruiting | Phase 3 | 463 | Eli Lilly and CompanyINDUSTRY | 4 | Feb 5, 2026 | clinicaltrials |
| NCT02246621 | A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer(MONARCH 3) | active not recruiting | Phase 3 | 493 | Eli Lilly and CompanyINDUSTRY | 22 | Feb 3, 2026 | clinicaltrials |
| NCT07371910 | Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer | active not recruiting | Phase 3 | 200 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06519370 | FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer | active not recruiting | Phase 3 | 350 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04320979 | Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients | active not recruiting | Phase 3 | 2,400 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04290793 | Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer | active not recruiting | Phase 2 / Phase 3 | 113 | Hebei Medical University Fourth HospitalOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT02051218 | Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks | active not recruiting | Phase 3 | 1,380 | Swiss Cancer InstituteOTHER | 3 | Dec 30, 2025 | clinicaltrials |
| NCT03997123 | Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC(CAPItello-290) | active not recruiting | Phase 3 | 923 | AstraZenecaINDUSTRY | 30 | Dec 22, 2025 | clinicaltrials |
| NCT04193059 | Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer(PANSY) | active not recruiting | Phase 3 | 1,560 | Fudan UniversityOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT04514419 | Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel | active not recruiting | Phase 3 | 408 | BioRay Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT03529110 | DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] | active not recruiting | Phase 3 | 524 | Daiichi SankyoINDUSTRY | 15 | Oct 21, 2025 | clinicaltrials |
| NCT06265428 | A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer | active not recruiting | Phase 3 | 228 | DualityBio Inc.INDUSTRY | 1 | Oct 20, 2025 | clinicaltrials |
| NCT05840211 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy(ASCENT-07) | active not recruiting | Phase 3 | 654 | Gilead SciencesINDUSTRY | 28 | Oct 3, 2025 | clinicaltrials |
| NCT05382286 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer(ASCENT-04) | active not recruiting | Phase 3 | 443 | Gilead SciencesINDUSTRY | 28 | Sep 18, 2025 | clinicaltrials |
| NCT04335669 | NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC | active not recruiting | Phase 3 | 325 | Lund University HospitalOTHER | 2 | Sep 12, 2025 | clinicaltrials |
| NCT04379570 | Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy | active not recruiting | Phase 3 | 1,167 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT05063786 | Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)(ALPHABET) | active not recruiting | Phase 3 | 27 | Spanish Breast Cancer Research GroupOTHER | 6 | Sep 8, 2025 | clinicaltrials |
| NCT04134598 | ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer(EUROPA) | active not recruiting | Phase 3 | 926 | Azienda Ospedaliero-Universitaria CareggiOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT05802225 | Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer(PREFER) | active not recruiting | Phase 3 | 398 | BiocadINDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT05257395 | A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer | active not recruiting | Phase 3 | 397 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT03725059 | Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) | active not recruiting | Phase 3 | 1,240 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Jul 11, 2025 | clinicaltrials |
Data updated 22 days agoSource updated May 19, 2026source: clinicaltrials